AMRI makes a promotion in Singapore
Takeshi Yura becomes senior director of drug discovery services
In this expanded role, Yura will take overall responsibility for site management, which includes leadership of the AMRI Singapore Research Centre's chemistry, biology and r&d operations.
Yura will replace Raymond Yeung, who has been managing director of the site from 2007.
Initially joining the Singapore subsidiary in January as assistant director of medicinal chemistry, Yura has more than 22 years of experience in discovery chemistry, project management and business development.
Prior to joining AMRI, he was a director at Dishman Japan, responsible for sales and business development activities. Before this he was discovery chemistry research head at Pfizer Japan, and section head of medicinal chemistry at Bayer Yakuhin.
‘Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership Dr Yura has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role,’ said Bruce Sargent, senior vp of drug discovery at AMRI.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
UK clinical trial reforms come into force in largest regulatory overhaul in 20 years
The MHRA and Health Research Authority are implementing the most significant package of clinical trial regulatory reforms in more than two decades, introducing faster assessment routes for lower-risk trials and mandatory registration of trial results
Research & Development
Epitopea receives MHRA approval for first-in-human trial of RNA vaccine for ovarian cancer
The company has received regulatory approval from the MHRA and Regional Ethics Committee to initiate its OVACT Phase I/Ib clinical trial of CryptiVax-1001, an off-the-shelf mRNA immunotherapy targeting high-grade serous ovarian cancer
Research & Development
NEUVIOR Pharmaceuticals receives Innovate UK grant to explore bio-based materials for circular pharmaceutical manufacturing
The Innovate UK feasibility grant will advance its ZYLON programme, which involves clean-chemistry lab trials exploring how bio-derived materials could replace harder-to-recycle packaging formats and reduce waste in pharmaceutical manufacturing
Research & Development
Awen Oncology secures seven-figure funding to advance rare bone cancer therapeutic programme
The cancer therapeutics company has secured seven-figure funding led by biotech investor Dr Urs Spitz to progress its lead programme targeting a rare form of bone cancer with potential broader oncology applications towards clinical development
Research & Development
Leinco Technologies and CellCarta partner to advance proteomics solutions for discovery and drug development
The pair have announced a strategic collaboration combining Leinco's IHC and spatial biology-validated antibody portfolio with CellCarta's CPTAC-validated Immuno-MRM assay resources to enhance proteomic analysis for immuno-oncology and targeted therapy development
Research & Development
Biognosys collaborates with Michael J. Fox Foundation to develop biomarker assays for Parkinson's research
The pair will work to develop highly sensitive, quantitative biomarker assays targeting LRRK2, the most common genetic risk factor for late-onset Parkinson's disease, in support of the foundation's global LITE initiative spanning more than 50 academic, industry and clinical partners